Transcriptomics

Dataset Information

0

RNA-seq analysis of CAR-NKAE cells and CD45RA- CAR-T cells


ABSTRACT: CAR-T cell therapy against MM currently shows promising results, but usually with serious toxicities. CAR-NK cells may exert less toxicity when redirected against resistant myeloma cells. CARs can be designed through the use of receptors, such as NKG2D, which recognizes a wide range of ligands to provide broad target specificity. Here, we test this approach by analyzing the anti-tumor activity of activated and expanded NK cells (NKAE) and CD45RA- T cells from MM patients that were engineered to express an NKG2D-based CAR. NKAE cells were cultured with irradiated Clone9.mbIL21 cells. Then, cells were transduced with an NKG2D-4-1BB-CD3z-CAR. CAR-NKAE cells exhibited no evidence of genetic abnormalities. Although memory T cells were more stably transduced, CAR-NKAE cells exhibited greater in vitro cytotoxicity against MM cells, while showing minimal activity against healthy cells. In vivo, CAR-NKAE cells mediated highly efficient abrogation of MM growth, and two of the treated mice remained disease-free. Overall, these results demonstrate that it is feasible to modify autologous NKAE cells from MM patients to safely express a NKG2D-CAR. Additionally, autologous CAR-NKAE cells display enhanced anti-myeloma activity demonstrating that they could be an effective strategy against MM supporting the development of NKG2D-CAR NK cell therapy for MM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE179408 | GEO | 2021/08/16

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2011-03-08 | E-GEOD-27838 | biostudies-arrayexpress
2011-03-08 | GSE27838 | GEO
| 2402632 | ecrin-mdr-crc
2023-09-26 | GSE243787 | GEO
2023-03-13 | GSE226956 | GEO
2023-03-29 | GSE228528 | GEO
2024-02-12 | GSE249316 | GEO
2021-05-17 | GSE166976 | GEO
2020-12-06 | GSE162716 | GEO
2024-07-10 | GSE271915 | GEO